

February 26, 2018

## Dai-ichi Life to Investment in CureApp, Inc.

### ～Third Impact Investment through Support for Treatment Applications～

Dai-ichi Life Insurance Company, Limited (the “Company;” President and Representative Director: Seiji Inagaki) has made its third impact investment of 200 million yen in CureApp, Inc. (“CureApp” President and CEO: Kota Satake), a Japanese startup company that develops mobile applications for the treatment of diseases.

CureApp is a startup company that develops and provides “treatment applications” that treat diseases through smartphones based on its medical knowledge. Treatment applications are expected to increase the effectiveness and efficiency of treatment, as it enables timely and appropriate support for patients according to individual conditions outside the scope of outpatient visits. As its first project, CureApp has conducted clinical trials of treatment applications for smoking cessation (treatment of nicotine addiction), aiming for the first pharmaceutical approval in Japan. CureApp has been also engaged in the research of treatment applications for other diseases.

It is expected that the widespread use of treatment applications will greatly contribute to the resolution of social issues such as decreasing the number of patients, extending healthy life expectancy, and reducing medical costs. The Company expects high investment returns through this investment while supporting CureApp’s efforts in creating positive social impacts through financial support.

The Company continues to improve its investment returns through enhancement and diversification of its investment methods, while proactively engaging in ESG investments in an effort to contribute to creating a sustainable society as a responsible institutional investor.

#### < Dai-ichi Life’s Impact Investment History >

Headline	Release date	URL
Dai-ichi Life to Engage in Impact Investment ～First Impact Investment in Gojo & Company, Inc. which provides support for micro-finance business～	Oct 23, 2017	<a href="http://www.dai-ichi-life.co.jp/english/news_release/2017/pdf/index_012.pdf">http://www.dai-ichi-life.co.jp/english/news_release/2017/pdf/index_012.pdf</a>
[Impact Investment] Investment in Spiber Inc. ～Second Impact Investment to Support for Development of New-Generation Bio-Materials	Oct 23, 2017	<a href="http://www.dai-ichi-life.co.jp/company/news/pdf/2017_044.pdf">http://www.dai-ichi-life.co.jp/company/news/pdf/2017_044.pdf</a>

Mr. Kota Satake, President and CEO of CureApp, Inc., commented:



“We are developing treatment applications, which enable medical support for patients outside the scope of medical consultations by doctors, providing high-quality treatment tailored to each patient. We also believe that these applications can contribute to the resolution of social issues such as medical cost reductions and regional disparities in receiving treatment. Through our business, we strive to establish a treatment methodology with the utilization of treatment applications in Japan, while we contribute to the creation of positive social impact that ESG investment aims for.”

[Company Outline]

Trade Name	CureApp, Inc.
Head Office	4th floor of Kodenma-cho YS Building, 12-5 Nihonbashi Kodenma-cho, Chuo-ku, Tokyo
Representative	Kota Satake (President and CEO)
Established	July 31, 2014
Capital	¥1,966,500,000
Business Description	Software medical device development, personal health records (PHR) services and mobile health-related services